Changes of plasma concentration of osteoprotegerin and its association with endothelial dysfunction before and after hypouricemic therapy in patients with hyperuricemia

Modern Rheumatology

Volumn 25, Issue 1, 2014, Pages 123-127

  Wang, Hao Hua ^a   Xiang, Guang Da ^b  

^a DONGGUAN PEOPLE'S HOSPITAL   (China)

^b WUHAN GENERAL HOSPITAL OF GUANGZHOU COMMAND   (China)

Author keywords

Endothelial function; Hyperuricemia; Osteoprotegerin; Serum uric acid

Indexed keywords

ALLOPURINOL; COLCHICINE; CORTICOSTEROID; OSTEOPROTEGERIN; PROBENECID; URICOSURIC AGENT;

ADULT; ARTERY DIAMETER; ARTICLE; BIOCHEMICAL ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ECHOGRAPHY; ENDOTHELIAL DYSFUNCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUID INTAKE; GOUT; HUMAN; HYPERURICEMIA; KIDNEY FUNCTION; MALE; MIDDLE AGED; PRIORITY JOURNAL; URIC ACID BLOOD LEVEL; URINE VOLUME; AGED; BLOOD; PATHOPHYSIOLOGY; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM;

ADULT; AGED; ALLOPURINOL; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERURICEMIA; MALE; MIDDLE AGED; OSTEOPROTEGERIN; PROBENECID; TREATMENT OUTCOME; URICOSURIC AGENTS;

EID: 84983387622     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/14397595.2014.926852     Document Type: Article

References (39)

1. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, et al. Osteoprotegerin -deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998;12(9):1260-8.
2. Kim SM, Lee J, Ryu OH, Lee KW, Kim HY, Seo JA, et al. Serum osteoprotegerin levels are associated with inflammation and pulse wave velocity. Clin Endocrinol(Oxf). 2005;63(5):594-8.
3. Reid P, Holen I. Pathophysiological roles of osteoprotegerin (OPG). Eur J Cell Biol. 2009;88(1):1-17.
4. Ciccone MM, Scicchitano P, Gesualdo M, Zito A, Carbonara R, Locorotondo M, et al. Serum osteoprotegerin and carotid intima-media thickness in acute/chronic coronary artery diseases. J Cardiovasc Med (Hagerstown). 2013;14(1):43-8.
5. Kim J, Song TJ, Yang SH, Lee OH, Nam HS, Kim YD, et al. Plasma osteoprotegerin levels increase with the severity of cerebral artery atherosclerosis. Clin Biochem. 2013;46(12):1036-40.
6. Choe JY, Lee GH, Kim SK. Radiographic bone damage in chronic gout is negatively associated with the inflammatory cytokines soluble interleukin 6 receptor and osteoprotegerin. J Rheumatol. 2011;38(3):485-91.
7. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992;340(8828): 1111-5.
8. Sánchez-Lozada LG, Lanaspa MA, Cristóbal-García M, García-Arroyo F, Soto V, Cruz-Robles D, et al. Uric Acid-induced endothelial dysfunction is associated with mitochondrial alterations and decreased intracellular ATP concentrations. Nephron Exp Nephrol. 2012;121(3-4):e71-8.
9. Agabiti-Rosei E, Grassi G. Beyond gout: uric acid and cardiovascular diseases. Curr Med Res Opin. 2013;29(Suppl 3):33-9.
10. Meléndez-Ramírez G, Pérez-Méndez O, López-Osorio C, Kuri-Alfaro J, Espinola-Zavaleta N. Effect of the treatment with allopurinol on the endothelial function in patients with hyperuricemia. EndocrRes. 2012;37(1):1-6.
11. Yelken B, Caliskan Y, Gorgulu N, Altun I, Yilmaz A, Yazici H, et al. Reduction of uric acid levels with allopurinol treatment improves endothelial function in patients with chronic kidney disease. Clin Nephrol 2012;77(4):275-82.
12. Schumacher HR, Chen LX. Gout and other crystal-associated artheropathies. In Fauci AS, editors. Harrison’s Rheumatology. New York: McGraw-Hill Medical; 2008:235-8.
13. Xiang GD, Pu JH, Sun HL, Zhao LS. Alpha-lipoic Acid Improves Endothelial Dysfunction in Patients with Subclinical Hypothyroidism. Exp Clin Endocrinol Diabetes. 2010;118(9):625-9.
14. Xiang G, Xiang L, Xiang L, Wang H, Dong J. Change of plasma osteoprotegerin and its association with endothelial dysfunction before and after exercise in Hashimoto’s thyroiditis with euthyroidism. Exp Clin Endocrinol Diabetes. 2012;120(9):529-34.
15. Sattler AM, Schoppet M, Schaefer JR, Hofbauer LC. Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease. Calcif Tissue Int. 2004;74(1): 103-6.
16. McGonigle JS, Giachelli CM, Scatena M. Osteoprotegerin and RANKL differentially regulate angiogenesis and endothelial cell function. Angiogenesis. 2009;12(1):35-46.
17. Kobayashi-Sakamoto M, Isogai E, Hirose K, Chiba I. Role of alphav integrin in osteoprotegerin-induced endothelial cell migration and proliferation. Microvasc Res. 2008;76(3): 139-44.
18. Di Bartolo BA, Schoppet M, Mattar MZ, Rachner TD, Shanahan CM, Kavurma MM. Calcium and osteoprotegerin regulate IGF1R expression to inhibit vascular calcification. Cardiovasc Res. 2011;91(3):537-45.
19. Bennett BJ, Scatena M, Kirk EA, Rattazzi M, Varon RM, Averill M, et al. Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/- mice. Arterioscler Thromb Vasc Biol 2006;26(9):2117-24.
20. Price PA, June HH, Buckley JR, Williamson MK. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol. 2001;21(10):1610-6.
21. Zwerina J, Hayer S, Tohidast-Akrad M, Bergmeister H, Redlich K, Feige U, et al. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum. 2004;50(1):277-90.
22. Van Campenhout A, Golledge J. Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis 2009;204(2):321-9.
23. Hosbond SE, Poulsen TS, Diederichsen AC, Nybo M, Rasmussen LM, Mickley H. Osteoprotegerin as a marker of atherosclerosis: a systematic update. Scand Cardiovasc J. 2012; 46(4):203-11
24. Simão AN, Lozovoy MA, Dichi I. The uric acid metabolism pathway as a therapeutic target in hyperuricemia related to metabolic syndrome. Expert Opin Ther Targets. 2012;16(12): 1175-87.
25. Chuang SY, Chen JH, Yeh WT, Wu CC, Pan WH. Hyperuricemia and increased risk of ischemic heart disease in a large Chinese cohort. Int J Cardiol. 2012;154(3):316-21.
26. Winnard D, Wright C, Jackson G, Gow P, Kerr A, McLachlan A, et al. Gout, diabetes and cardiovascular disease in the Aotearoa New Zealand adult population: co-prevalence and implications for clinical practice. N Z Med J. 2012;126(1368):53-64.
27. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction, a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol. 2003; 23(2): 168-75.
28. Xiang GD, Sun HL, Zhao LS. Changes of osteoprotegerin before and after insulin therapy in type 1 diabetic patients. Diabetes Res Clin Pract. 2007; 76(2):199-206
29. Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu W, et al. Hyperuricemia induces endothelial dysfunction. Kidney Int. 2005;67(5): 1739-42.
30. Dogan A, Yarlioglues M, Kaya MG, Karadag Z, Dogan S, Ardic I, et al. Effect oflong-term and high-dose allopurinol therapy on endothelial function in normotensive diabetic patients. Blood Press. 2011;20(3): 182-7.
31. Nieto FJ, Iribarren C, Gross MD, Comstock GW, Cutler RG. Uric acid and serum antioxidant capacity: a reaction to atherosclerosis? Atherosclerosis. 2000; 148(1): 131-9.
32. Bagnati M, Perugini C, Cau C, Bordone R, Albano E, Bellomo G. When and why a water-soluble antioxidant becomes pro-oxidant during copper-induced low-density lipoprotein oxidation: a study using uric acid. Biochem J. 1999;340(Pt 1): 143-52.
33. Förstermann U. Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies. Nat Clin Pract Cardiovasc Med. 2008; 5(6):338-49.
34. Nedeljkovic ZS, Gokce N, Loscalzo J. Mechanisms of oxidative stress and vascular dysfunction. Postgrad Med J. 2003;79(930): 195-9.
35. George J, Carr E, Davies J, Belch JJ, Struthers A. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation. 2006;114(23):2508-16.
36. Aydin H, Deyneli O, Yavuz D, Yüksel M, Targin O, Yazici D, et al. Effect of oxidative stress on aorta and tibia osteoprotegerin gene expression in ovariectomized rats. Minerva Endocrinol 2011;36(2):107-15.
37. Matsubara K, Stenvinkel P, Qureshi AR, Carrero JJ, Axelsson J, Heimbürger O, et al. Inflammation modifies the association of osteoprotegerin with mortality in chronic kidney disease. J Nephrol. 2009;22(6):774-82.
38. Zapolski T, Waciński P, Kondracki B, Rychta E, Buraczynska MJ, Wysokiński A. Uric acid as a link between renal dysfunction and both pro-inflammatory and prothrombotic state in patients with metabolic syndrome and coronary artery disease. Kardiol Pol. 2011;69(4): 319-26.
39. Rhee EJ, Lee WY, Kim SY, Kim BJ, Sung KC, Kim BS, et al. Relationship of serum osteoprotegerin levels with coronary artery disease severity, left ventricular hypertrophy and C-reactive protein. Clin Sci (Lond). 2005;108(3):237-43.